Slingshot members are tracking this event:
GlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|GLYC||Community voting in process|